Results 111 to 120 of about 148,298 (266)

Allergic Rhinitis Amplifies Asthma Risk in Patients With Chronic Rhinosinusitis: A Large‐Scale Retrospective Cohort Analysis

International Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background Chronic rhinosinusitis (CRS) and allergic rhinitis (AR) are two highly prevalent airway diseases in the United States. While the coexistence of CRS and asthma is well recognized, less is known about the development of new‐onset asthma in CRS, particularly in the context of comorbid AR. This study assessed the impact of CRS and AR on
Austin J. Lee, Mohamad R. Chaaban
wiley   +1 more source

Extent of Sinus Surgery Is Associated With Disease Control in Biologic Treated Type 2 Dominant CRS

International Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background A greater benefit of biologics is observed after surgery in Type 2 chronic rhinosinusitis with nasal polyps (CRSwNP). However, the extent of surgery remains undefined in many studies. This study evaluated the extent of surgery on disease control in patients receiving biologics for refractory Type 2 dominant CRSwNP.
Nicholas J. Campion, Peta‐Lee Sacks, Lu Hui Png, Ruoxin Hua, Rhea Darbari Kaul, Raquel Alvarado, Christine Choy, Raymond Sacks, Peter Earls, Raewyn G. Campbell, Larry Kalish, Richard J. Harvey   +11 more
wiley   +1 more source

Current status and influencing factors of laryngopharyngeal reflux disease in outpatients with laryngeal diseases: key considerations for clinical practice. [PDF]

Front Med (Lausanne)
Zhang L, Wu Y, Yang Y.
europepmc   +1 more source

Epidurography for Outpatients [PDF]

Journal of the Royal Society of Medicine, 1983
openaire   +2 more sources

Inflammatory Signatures Beyond Th1/Th2 Endotypes Provide Insights Into Postoperative Recurrence in Chronic Rhinosinusitis

International Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background Chronic rhinosinusitis (CRS) represents a spectrum of inflammatory endotypes, driven by distinct T helper (Th) immune responses. The high rate of recurrent disease despite appropriate medical and surgical interventions highlights the need for improved characterization beyond the traditional type 2 and non‐type 2 phenotypes to better
Liyona Kampel, Narin N. Carmel, Shaun Edalati, Hen Chaushu, Forsan Jahshan, Yaniv Hadi, Timur Pestrikov, Leonor Leider Trejo, Nidal Muhanna, Avraham Abergel   +9 more
wiley   +1 more source

Economic burden of <i>Mycoplasma pneumoniae</i> infection in Jinhua City, China: a multicenter cross-sectional study. [PDF]

Front Public Health
Du ZP, Feng YL, Ma X, Ye Z, Li XC, He JJ, Jiang GY, Zhou L, Long ZP, Pang ZF, Zhang GM.   +10 more
europepmc   +1 more source

Healing Following Endoscopic Reconstruction of the Anterior Skull Base in Patients With Sinonasal Malignancies

International Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background Healing dynamics after anterior skull base (ASB) reconstruction following transnasal endoscopic surgery (TES) for sinonasal malignancies remain poorly characterized. This study aimed to describe the postoperative healing process, quantify time to healing, identify factors influencing healing, and assess radiologic evolution over ...
Giacomo Contro, Leonardo Calvanese, Piergiorgio Gaudioso, Stefano Taboni, Mosè Sozzi, Gloria Schiavo, Alessandra Sordi, Isabelle Dohin, Francesca Mularoni, Giuseppe Roccuzzo, Ester Orlandi, Barbara Vischioni, Gianluca Dalfino, Carlotta Pessina, Roberto Maroldi, Mario Turri‐Zanoni, Cesare Piazza, Paolo Battaglia, Maurizio Bignami, Paolo Castelnuovo, Davide Mattavelli, Piero Nicolai, Marco Ferrari   +22 more
wiley   +1 more source

Receipt of Medicines Information From the Internet and Other Information Sources Among Adult Medicine Users in Developed Economies, 2010-2025: Systematic Review. [PDF]

J Med Internet Res
Mononen N, Salo MM, Timonen D, Pohjanoksa-Mäntylä M, Airaksinen M.   +4 more
europepmc   +1 more source

Comparable Infection Risk of Ocrelizumab and Rituximab in Multiple Sclerosis in a Nationwide Swedish Cohort Study

Annals of Neurology, EarlyView.
In multiple sclerosis (MS), anti‐CD20 therapies have been associated with increased infection risk, but whether this risk differs between rituximab and ocrelizumab is not known. Using a nationwide cohort, we studied infection risk and relapse outcomes among 16,872 treatment episodes with rituximab, ocrelizumab, or other disease‐modifying therapies ...
Thomas Frisell, Sebastian Hedberg, Fredrik Piehl   +2 more
wiley   +1 more source

Psychosocial and Behavioral Correlates of Self-Rated Health in Psychiatric Outpatients and Community Adults. [PDF]

Psychiatry Investig
Ko Y, Kim SG, Lee SI, Lee J, Jung HY, Youn H.   +5 more
europepmc   +1 more source